Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical Failure

Anticancer Res. 2017 Dec;37(12):6943-6946. doi: 10.21873/anticanres.12159.

Abstract

Background/aim: We previously reported the use of mass spectrometry and western blotting to identify proteins from tumour regions of formalin-fixed paraffin-embedded biopsies from 16 men who presented with apparently localized prostate cancer, and found that annexin A2 (ANXA2) appeared to be a better predictor of subsequent biochemical failure than prostate-specific antigen (PSA).

Materials and methods: In this follow-up study, ANXA2 and PSA were measured using western blotting of proteins extracted from biopsies from 37 men from a subsequent prostate cancer trial.

Results: No significant differences in ANXA2 and PSA levels were observed between men with and without biochemical failure. The statistical effect sizes were small, d=0.116 for ANXA2, and 0.266 for PSA.

Conclusion: ANXA2 and PSA proteins measured from biopsy tumour regions are unlikely to be good biomarkers for prediction of the clinical outcome of prostate cancer presenting with apparently localized disease.

Keywords: FFPE sections; PSA; Prostate cancer; annexin A2; proteins.

MeSH terms

  • Annexin A2 / metabolism*
  • Biopsy
  • Blotting, Western
  • Chemoradiotherapy
  • Humans
  • Male
  • Outcome Assessment, Health Care
  • Prognosis
  • Prostate / metabolism*
  • Prostate / pathology
  • Prostate-Specific Antigen / metabolism*
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy

Substances

  • Annexin A2
  • Prostate-Specific Antigen